Search

Your search keyword '"Prevymis®"' showing total 7 results
Start Over Descriptor "Prevymis®"
7 results on '"Prevymis®"'

1. Evaluación positiva de medicamentos: septiembre, octubre y noviembre 2017.

Author

García Luque, A., Puerro Vicente, M., Sánchez López, P., and López Morán, M. J.

Subjects
*CLINICAL drug trials, *MEDICAL personnel, *HEALTH products, *MEDICAL supplies
Abstract

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

2. Evaluación positiva de medicamentos: septiembre, octubre y noviembre 2017.

Author

García Luque, A., Puerro Vicente, M., Sánchez López, P., and López Moran, M. J.

Abstract

Copyright of Sanidad Militar is the property of Ministerio de Defensa, Subdireccion General de Publicaciones y Patrimonio Cultural and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2018
Full Text
View/download PDF

3. Evaluación positiva de medicamentos: septiembre, octubre y noviembre 2017

Author

García Luque, A, Puerro Vicente, M, Sánchez López, P, and López Morán, MJ

Subjects
Mvasi®, Human thrombin, Jorveza®, Niraparib, Trelegy Ellipta®, Ocrevus®, Padeliporfine, Padeliporfina, Human fibrinogen, Budesonida, Umeclidinium, Ocrelizumab, Vilanterol, Budesonide, Zubsolv®, Elebrato Ellipta®, VeraSeal®, Prasterone, Naloxona, Guselkumab, Prasterona, Buprenorfina, Adynovi®, Naloxone, Trombina Humana, Fasenra®, Rurioctocog Alfa Pegol, Nyxoid®, Benralizumab, Tremfya®, Intrarosa®, Buprenorphine, Bevacizumab, Zejula®, Fibrinógeno humano, Fluticasone, Fluticasona, Letermovir, Prevymis®, Tookad®
Abstract

RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en septiembre, octubre y noviembre de 2017. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento. SUMMARY The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Published
2018

4. Evaluación positiva de medicamentos: septiembre, octubre y noviembre 2017

Author

García Luque,A, Puerro Vicente,M, Sánchez López,P, and López Morán,MJ

Subjects
Mvasi®, Jorveza®, Niraparib, Trelegy Ellipta®, Ocrevus®, Padeliporfina, Budesonida, Umeclidinium, Ocrelizumab, Vilanterol, Zubsolv®, Elebrato Ellipta®, VeraSeal®, Naloxona, Guselkumab, Prasterona, Buprenorfina, Adynovi®, Trombina Humana, Fasenra®, Rurioctocog Alfa Pegol, Nyxoid®, Benralizumab, Tremfya®, Intrarosa®, Bevacizumab, Zejula®, Fibrinógeno humano, Fluticasona, Letermovir, Prevymis®, Tookad®
Abstract

RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en septiembre, octubre y noviembre de 2017. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento.

Published
2018

5. Inyección de letermovir.

Abstract

Copyright of ASHP Patient Medication Information - Spanish Version is the property of American Society of Health System Pharmacists and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022

6. Letermovir.

Abstract

Copyright of ASHP Patient Medication Information - Spanish Version is the property of American Society of Health System Pharmacists and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022

7. Letermovir Injection.

Abstract

Letermovir injection is used to help prevent cytomegalovirus (CMV) infection and disease in certain people who have received a hematopoietic stem-cell transplant (HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow) and are at increased risk of developing a CMV infection. Letermovir is in a class of medications called antivirals. It works by slowing the growth of CMV. [ABSTRACT FROM PUBLISHER]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results